PSTI - Pluristem Therapeutics Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.17
0.00 (0.00%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close1.17
Open1.16
Bid1.08 x 2900
Ask1.27 x 2900
Day's Range1.15 - 1.17
52 Week Range1.06 - 1.65
Volume150,033
Avg. Volume226,998
Market Cap135.487M
Beta (3Y Monthly)1.86
PE Ratio (TTM)N/A
EPS (TTM)-0.25
Earnings DateFeb 13, 2019 - Feb 18, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.67
Trade prices are not sourced from all markets
  • GlobeNewswire2 days ago

    New Findings from Pluristem’s Phase II IC study: PLX-PAD Cells Significantly Improves Blood Glucose Control (HbA1c) and Reduce Chronic Inflammation

    Pluristem Therapeutics Inc. (PSTI) (PSTI.TA), a leading regenerative medicine company developing novel placenta-based cell therapy products, today announced that the Company presented additional data from its Phase II clinical study evaluating PLX-PAD for the treatment of Intermittent Claudication (IC) at the 2018 American Heart Association Scientific Sessions in Chicago. The data were presented by Prof. Norbert Weiss, MD, Director of the Vascular Center at the Technical University of Dresden, Germany, and the lead European Principal Investigator for the Phase II IC study.

  • Associated Press5 days ago

    Pluristem: Fiscal 1Q Earnings Snapshot

    The Haifa, Israel-based company said it had a loss of 8 cents per share. The biotechnology company posted revenue of $4,000 in the period. The company's shares closed at $1.18. A year ago, they were trading ...

  • GlobeNewswire6 days ago

    Pluristem Therapeutics Reports Fiscal 2019 First Quarter Results and Provides Corporate Update

    Pluristem Therapeutics Inc. (PSTI) (PSTI.TA), a leading regenerative medicine company developing novel placenta-based cell therapy products, today reported financial results for its fiscal first quarter 2019 ended September 30, 2018 and provided a corporate update. “We were very pleased to announce this quarter on FDA approval of an expanded access program that will provide critical limb ischemia patients who are not suitable for enrollment in our Phase III trial with access to PLX-PAD while the trial is ongoing,” said Yaky Yanay, Co-Chief Executive Officer and President of Pluristem. “During the fiscal first quarter and subsequent period, we continued to make progress advancing our pipeline of novel placenta-based cell therapy products in multiple indications.” Mr. Yanay continued, "We are making good progress in enrolling patients in both ongoing Phase III clinical trials of PLX-PAD in critical limb ischemia (CLI) and the treatment of muscle injury following hip fracture.

  • GlobeNewswire27 days ago

    Pluristem Therapeutics Selected to Present Data from Phase II IC Study at the American Heart Association Scientific Sessions

    Pluristem Therapeutics Inc. (PSTI) (PSTI.TA), a leading regenerative medicine company developing novel placenta-based cell therapy products, today announced that the Company will be presenting at four conferences during November: at the BioEurope conference, which is being held November 5–7, 2018 in Copenhagen, at the 15th Annual Vascular Interventional Advances (VIVA) Conference, which is being held November 5-8 in Las Vegas, at the 2018 American Heart Association (AHA) Scientific Sessions, which are being held November 10-12 in Chicago and the Cell and Gene Therapy Manufacturing conference, which is being held November 14-15 in London. At the AHA Scientific Sessions, Prof. Norbert Wiess, the Principal Investigator of the Company’s Phase II intermittent claudication (IC) study, will present detailed results from the study.

  • GlobeNewswire29 days ago

    U.S. FDA Approves Cost Recovery for PLX-PAD under Expanded Access Program in the Treatment of Critical Limb Ischemia

    Pluristem Therapeutics Inc. (PSTI) (PSTI.TA), a leading regenerative medicine company developing novel placenta-based cell therapy products, and WideTrial Inc., a privately-held third-party sponsor of authorized Expanded Access Programs (EAPs), today announced that the parties have entered into agreement to initiate an FDA-cleared EAP for Pluristem’s cell therapy product, PLX-PAD, for the treatment of critical limb ischemia (CLI). The parties further announced that the FDA has authorized WideTrial to charge payment for the PLX-PAD EAP treatment.

  • GlobeNewswirelast month

    Pluristem Therapeutics Announces Publication in JCSM of Two-Year Follow-Up Data from Phase I/II Study in Muscle Regeneration and European Clearance for Ongoing Phase III Study

    Pluristem Therapeutics Inc. (PSTI) (PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products, today announced that two-year follow-up data from its Phase I/II clinical study evaluating its allogeneic placenta-derived cell therapy product, PLX-PAD, for the treatment of muscle injury following hip replacement was published in the peer-reviewed Journal of Cachexia, Sarcopenia and Muscle. Pluristem also announced that its ongoing Phase III study in the treatment of muscle injury following hip fracture, which is underway in the U.S. and Israel, has been cleared to enroll additional patients in Denmark, Germany and the United Kingdom.

  • GlobeNewswire2 months ago

    Pluristem Reports Fiscal 2018 Fourth Quarter Results and Provides Corporate Update

    Pluristem Therapeutics Inc. (PSTI) (PSTI.TA), a leading regenerative medicine company developing novel placenta-based cell therapy products, today reported financial results for its fourth quarter and fiscal year ended June 30, 2018 and provided a corporate update. “The indications we are pursuing for our novel cell therapy products, PLX-PAD and PLX-R18, target underserved medical conditions for which there are no viable treatment options today,” stated Yaky Yanay, Co-Chief Executive Officer and President of Pluristem.

  • What does Pluristem Therapeutics Inc’s (NASDAQ:PSTI) Balance Sheet Tell Us About Its Future?
    Simply Wall St.2 months ago

    What does Pluristem Therapeutics Inc’s (NASDAQ:PSTI) Balance Sheet Tell Us About Its Future?

    Pluristem Therapeutics Inc (NASDAQ:PSTI), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. However, the trade-off is PSTIRead More...

  • Benzinga3 months ago

    Pluristem Therapeutics, Rexahn Pharma Are Biotech Winners, B Riley FBR Says In Bullish Initiation

    With hundreds of biotech stocks all assuring big prospects, building a portfolio of truly transformative medicine makers is a feat. B. Riley FBR said it's found two winners.  The Analyst Analyst  George ...

  • ACCESSWIRE4 months ago

    Free Technical Reports on Portola Pharma and Three Additional Biotech Equities

    LONDON, UK / ACCESSWIRE / July 19, 2018 / If you want a free Stock Review on PTLA sign up now at www.wallstequities.com/registration. WallStEquities.com revisits the Biotech space, which focuses on novel drug development and clinical research aimed at treating diseases and medical conditions. Under evaluation this morning are the following equities: Pluristem Therapeutics Inc. (NASDAQ: PSTI), Portola Pharmaceuticals Inc. (NASDAQ: PTLA), Recro Pharma Inc. (NASDAQ: REPH), and Regeneron Pharmaceuticals Inc. (NASDAQ: REGN).

  • Should You Be Content With Pluristem Therapeutics Inc’s (NASDAQ:PSTI) Earnings Growth?
    Simply Wall St.5 months ago

    Should You Be Content With Pluristem Therapeutics Inc’s (NASDAQ:PSTI) Earnings Growth?

    In this article, I will take a look at Pluristem Therapeutics Inc’s (NASDAQ:PSTI) most recent earnings update (31 March 2018) and compare these latest figures against its performance over theRead More...

  • Benzinga5 months ago

    Benzinga Pro's 5 Stocks To Watch Today

    Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Pluristem Therapeutics Inc. (NASDAQ: PSTI ) stock ...

  • Reuters5 months ago

    Israel's Pluristem sees positive results from leg pain study

    Israel's Pluristem Therapeutics Inc, a developer of placenta-based stem cell products, said on Tuesday it had positive results from a mid-stage study of its therapy to treat leg pain known as intermittent ...

  • Options Traders Expect Huge Moves in Pluristem Therapeutics (PSTI) Stock
    Zacks5 months ago

    Options Traders Expect Huge Moves in Pluristem Therapeutics (PSTI) Stock

    Investors in Pluristem Therapeutics (PSTI) need to pay close attention to the stock based on moves in the options market lately.

  • Pluristem Therapeutics Inc (NASDAQ:PSTI): Are Analysts Optimistic?
    Simply Wall St.6 months ago

    Pluristem Therapeutics Inc (NASDAQ:PSTI): Are Analysts Optimistic?

    Pluristem Therapeutics Inc’s (NASDAQ:PSTI): Pluristem Therapeutics Inc., together with its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. The US$156.33M market-cap posted a loss in its most recentRead More...

  • Associated Press6 months ago

    Pluristem: Fiscal 3Q Earnings Snapshot

    The Haifa, Israel-based company said it had a loss of 1 cent per share. The company's shares closed at $1.33. A year ago, they were trading at $1.32. _____ This story was generated by Automated Insights ...